8-K Announcements
6May 8, 2026·SEC
Mar 10, 2026·SEC
Nov 18, 2025·SEC
Ultralife Corporation (ULBI) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to achieve consistent profitability, highlighted by a net margin of -1.0% in 2026Q1 and a negative retained earnings balance of -$40.8 million, suggests that the current business model lacks the necessary operating leverage to justify a long-term position.
Ultralife Corporation (ULBI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Ultralife Corporation (ULBI) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.03vs $0.15-120.0% | $47Mvs $52M-9.5% |
| Q2 2026 | Mar 10, 2026 | $0.12vs $0.24-50.0% | $48Mvs $57M-14.9% |
| Q4 2025 | Nov 18, 2025 | $0.07vs $0.21-133.3% | $43Mvs $53M-18.2% |
| Q3 2025 | Aug 7, 2025 | $0.07vs $0.22-68.2% | $49Mvs $53M-8.4% |
Key metrics vs top competitors for Ultralife Corporation (ULBI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.11 | $101.77M | -17.46 | 16.24% | -3.09% | -4.46% | — | |
| $0.82 | $14.36M | -2.05 | 9.22% | -12.48% | -737.52% | — | |
| $0.55 | $48.56M | -5.48 | 10.52% | -7.43% | -0.06% | — | |
| $1.17 | $389.79M | -13.00 | 12.56% | -11.52% | -10.76% | — | |
| $34.96 | $478.44M | -60.28 | 19.56% | -6.32% | -3.4% | — | |
| $0.81 | $8.06M | -0.91 | 13.03% | -55.45% | -79.65% | — |
Ultralife Corporation (ULBI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Ultralife Corporation (ULBI) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 8, 2026·SEC
Mar 10, 2026·SEC
Nov 18, 2025·SEC
Get notified when ULBI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Ultralife Corporation (ULBI) stock FAQ — growth, dividends, profitability & financials explained
Ultralife Corporation (ULBI) reported $187.9M in revenue for fiscal year 2025. This represents a 1144% increase from $15.1M in 1996.
Ultralife Corporation (ULBI) grew revenue by 16.2% over the past year. This is strong growth.
Ultralife Corporation (ULBI) reported a net loss of $8.2M for fiscal year 2025.
Ultralife Corporation (ULBI) has a return on equity (ROE) of -4.5%. Negative ROE indicates the company is unprofitable.
Ultralife Corporation (ULBI) generated $6.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.